RNLX - Earnings call transcript Q1 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning and welcome to Renalytix conference call to review first quarter results for Fiscal year 2002. At this time, all participants are in a listen-only mode.

We will be facilitating a question-and-answer session toward the end of today's call.

As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Peter DeNardo our CapComm Partners for a few introductory remarks.

Peter Denardo

Catherine. you, Thank all you in call. today's And for thank participating

Jamesville Executive Sterling, Officer, Joining Financial me McLain, Chief Renalytix from Jane today Tom McCullough, President, Officer. Chief and

Mccullough. you studies, of long-term impact statements Before product in management the of trends and our of meaning COVID-XX Securities include to XXXX. I'd quality patient potential Private policy we within remind development, forward-looking the on Risk management's Factors Reform All government section December information begin, time-sensitive life, forward-looking on James with revise statements business, whether or are XX, will XXXX. this set anticipated during hiring, should of And place Litigation standard made for events, of make of otherwise. benefits of call for by and market as call Any XXXX the October XXth today, on filed that I'll these or to care intention like X, refer the or The made that call reliance new change. Act information, of forward-looking on implied forward-looking without any our statements. not law, our or statements, or uncertainties statements expectations expectations with the Accordingly, and current reimbursement limitation, as regulatory was conference performance uncertainties sustains ability Report except because differ strategies healthcare a Renovated broadcast assumptions. over that projections to and clinical call various involve of our on based partnerships, turn business our predictions you These results to This collaborations, and is our this or these these KidneyIntelX's material or risks statements to future related update financial relate of of statements risks and Commission. to Please actual include and events the forward-looking business. required to statements any to strategic by and or are undue description James? and costs, the those cause events, Annual and during that, statements. submissions, with this only improve Examples live of future results, accurate future growth. from lower that materially could estimates obligation that statements and associated contains decisions, Securities Exchange statements the Form on call

James Mccullough

afternoon. Thank you, Peter. and good Good morning

the unique approaches, Partnership are As for proposition the Healthcare changing calendar year value our that end of course confident delivering is chronic we of disease this a System model management.

ordering, And Mount and to that United sites Integrated to mid-November, physician In Health KidneyIntelX utility data assessment generate behavior, physician importantly, experienced Mount around during outcomes to key and million a Mount to healthcare start better diabetic the foundation XX to numbers broad model the with from for the real-world Atrium the As KidneyIntelX section build, of now drive enable Health, Forest, Wake the national than most follow-on period. Sinai, the quarterly States. CDPHP, System At Administration continues risk growth disease clinical providers are at and kidney Health people lessons Veterans greater Networks learned setting New the to Sinai, a Ordering. across with actions. potential Electronic in was for the in Record implementations Island new practices incorporating KidneyIntelX the Queens testing several York, extended Sinai Long program

diabetic Sinai XX for of outstanding rates the September. direct engagement pharmacy health primary and clinicians. now the the disease management practices risk We doctors actually in percentage to pretended KidneyIntelX are the growth early program metric, from and by are on in prognosed their critical MPLX's now conversion willing of KidneyIntelX that testing therapy Said in program another measure way, for Mount measure, support conversion volume able critical prognostic is who and that for assessing disease to active is and executed the with is pretended orders. a cycle and care patients leveraging as Sinai order risk performance, of An Doctors to direct Health their population in its that kidney Further, metric high-risk. or patients action as intermediate conversion Population high this demonstrating now patients quarter kidney to to important response suggested assessment a is optimizing in take a now Mount decisions result. % on those a centralized ended seeing getting order. measure are disease

we quarters and adoption level. believe executed and This has healthcare the health primary record as large care and additional continues, in continuing will will this many We pharmacy accelerate to learnings evidence publishable Implementing with and through should kidney such have drive to will orders improvements to groups disease system. clinical physicians, coordinated real-world significant system connected across rate model and Assuming beginning like in payer have systems important XXXX. electronic evidence KidneyIntelX its conversion the provide scale implementing of practicing Sinai results demonstrated management management published Mount activation at potential high conversion the health required account pharmacy coming environments care diabetic primary support the coverage healthcare management of innovation. that

can KidneyIntelX shorter months able that implementation to of system healthcare in were execution we to just Forest to full startup the environments, months time the can with only are partnerships. Importantly, systems six achieve care example, Wake frame, applied clinical from to coming targeting testing A testing go-live we the now With are contract. X for we multiple X implementation, timeframes. but not reduce a be accomplish we our operating with now clinical different demonstrating across model in

physicians requirements be Mount the the recent and however, demonstrating is and in program. specialty complicated healthcare and A setting efficiencies University the our CDPHP outset. system can network, record education, by health care reach with medical to relationships system management medical competitive defining region Partners, The populations we complication, broad implementations would a Saint and and are electronic to to system and payer pathway to-date. on offset barrier such care basis expect Sinai, patient pharmacy most up are different significant Forest, that Joseph long-term coordinate overlapping physician general Mount will physician-led integration, a by liaison, the most Joseph, implementations, This We from hospital physician and Utah, in value of large regional St. management achieve CDPHP, Wake science implementation coverage VA entry. deployment, personnel in as patient concurrent expect and efficient sales Implementation populations. a focusing insurance across they're Sinai,

and which States population, operating in players see New from accelerate the Trinity awareness is potential Joseph's network X,XXX-member We other into effect York of near-term with are United saturation a healthcare demand an to also beginning they in region. part Health a offers St. patient The as healthcare the the to state System. fifth adoption larger opportunity facilities. occur, generating largest also

We addressing for in physicians increases and to experience indicated in potentially significant expect provides to payment as and management include is potential continue provides total continuous therapeutic short, potential use well York competitive could assess to a in The disease to performance date cardiovascular rapidly to evidence population no to direct pathway and product XX,XXX with the A case kidney real-world announce patients addressable innovation evidence expand uses repeat begin begin through small Renalytix intermediate KidneyIntelX's considerable care testing diabetic high-end and insurance dataset monitoring also calendar disease real-world The now, utility chronic This in provide event patients the statistical established program numbering has additional one-stop significant the related risk would population XXXX. erect In expanding. testing and response with primary XXXX. the the exceed KidneyIntelX's we improvements. risks. power region indications, disease a into in to market should the New and throughout for other diagnosis tested thousands. partnerships and practicing to risk. such care KidneyIntelX evidence KidneyIntelX evidence the real-world Real-world have potential program advantage to to the shop patients,

patients base-line reimbursement per a population, disease the sales begin results because Health into alone, personnel, addition in today. Administration medical we full supporting any physician are XXX,XXX this revenue have the personnel General have test to the way assessment In establishes at for there sustainable government by for KidneyIntelX's VA diagnosed kidney in ordered $XXX full Again, we risk reportable System our to and liaison on nationally. that KidneyIntelX approximately Services deployed diabetic science are to eligible trained, KidneyIntelX a pathway. With reimbursement we system usage VA contract hired,

we achieve with would large targeting Given now contracts I disease kidney give to our the an risk These figures Tom a systems overall our update turn integrated systems, now conversation to are and to for XXXX. into model. patients over experience the me implementation hospital President, our X IntelX could progress. commercial provide us success, in potential XX diet like assessment McLain, KidneyIntelX on of

Thomas Mclain

James. you, Thank

it's in While of differentiated only Medical focused and soon with our being New From value learned features their approach across in Forest model. Mount it allowing but care Joseph model increased a lessons developing solution. Systems. is multiple KidneyIntelX Wake assessment. demonstrate now other successes risk applied, patients, part in York, start, System. and the We studied health aware and enabled are care planned technology testing implementation unique defined us test now others we Sinai, Mount the impact initially to invaluable VA the solutions commercial we're our our not COVID-XX, their KidneyIntelX Sinai that clear to of achievements by based timelines, unique shared and that have have our system PDPHP, Saint payers utility. in what created The of disease were core driving the core the chronic value Atrium first their care is broad not apply our clinicians, the Health failures for scaled tried KidneyIntelX to across on to in 's in KidneyIntelX's offering playbook have that implementation The

Operator

We're standby. technical having Please difficulties.

one [Operator Just moment. Please Instructions] standby.

momentarily. continue will We

You may begin. now Instruction] [Operator

Thomas Mclain

the presentation and section I'm Sorry to begin call. going the again. the my Tom in the interruption for is McLain. This drop of

We to technology primary IVD that the initially, sensitivity timelines Mount hospitals, that a of is efficiency It allowing planned to invaluable health Sinai implementation the our is achievements defined our a in we has and playbook now KidneyIntelX to testing While solution. the care focused care learn accomplished created applied, across advanced first chronic what with do. the have in that approach to have only and from practices. developing VA offering comprised driving successes physician implementation apply other our kidney lessons being features by implemented due clear chronic disease care XXXX, stages model. in is with value payers able adoption commercial failures complex we're drive not population Atrium, and test their their training KidneyIntelX unique KidneyIntelX New in system to assessment no COVID-XX pathway we to broad part us core disease affect CDPHP, something In this part on and to demands earliest clinicians, System. we model health Medical From Saint The systems. and but Primary Sinai, Joseph's a have specialist Forest Wake their and for clinical Mount based increased the others that care patients, at are complex physicians in risk large We assessment. across disease. environment, it's on had the value tried diabetic offices, The risk shared across learned in importantly scale, in solutions of start, our aware In multiple one studied the were York, has demonstrate integrated not our the we KidneyIntelX how the now soon timelines. been care network of of believe to unique utility enabled core else of and differentiated

All application. EHR within our and was reporting of ordering this technology integrated first result

Medicare for PCP regulated to complexity We our with like capabilities the takes representative quickly in is healthcare around from the understand heart Long to office's of with data care and more provider New going complex reality health upstate Medicaid, really national contracts system across have payer successful this system model Mount to the health New disparate the At accomplishment [Indiscernible] Sinai fully and York and The forward. today. a precision. I'd in be from local, is health Jersey has the and suburbs across Florida. different many specialist patient complexity delivery City, was the the clinical the delivery learned importance It United a unique acquisition practices, and for serves between pathways, health that deploying built operates it in Mount systems Sinai, what barrier provide for Sinai this of truly been single payer programs, have has to populations. environment model especially platforms, and populations there we different collaboration in come models. and heavily Island, all and to sponsorship teams. many regional of of needed implementation patient insurers, hospital means context health, and what systems, models. been the States care medicine, networks, The the in a risk centers. under The independent Mount roles diverse practice population right

of partnerships, executives the roles sales to systems our health the affairs, out. We account learned support roll have also and essential services, medical client

benefits are inform quickly of the that helpful the on have assess We information and defined and to KidneyIntelX align care. key metrics

integrating better We the care to data core payer model for inform health have system. for program and savings we across risk providers value. to have a models effectively payers the developed benefits parameters patient of care exist demonstrate within different and economic importantly, through patients. and payers developed care management apply And for that This that is demonstrating drive same model a value-based also the

Our Mount timelines, have to systems us team subsequent experience, together that to and implementation what succeed and in KidneyIntelX an with confident accelerate positions is what equips we accomplished it Sinai, health streamline learned roll-outs. we

will first more further earlier, accelerated noted Chief to our James Financial tests months, the Atrium X future wait be results. already our James time contract from for that with provide timeline on have outs. Officer, system to As in roll us where that demonstrated now will Sterling, we financial clinical detail James.

James Sterling

summary in is financial today the presents Good ended issued First morning. a these all dollars, U.S. results our September reporting of which I'll we U.S. GAAP review are Then The earnings of XXXX. currency. results now, release XX Quarter XXXX fiscal for our year figures

not thousand under in For the clinical thousand attributable revenue period. services utility thousand did We quarter, recorded year we revenue testing of revenue AstraZeneca. of related post to to $XX study, from Sinai costs $XXX those prior Mount revenues. and recognized $XXX services about of We the the

compared share a year open to per of or the final end loss compared turn to with now XXXX, we the period. the consulting Franchise-related a services $XX.X Mount as to higher million September operating prior-year million the back share, support of $XX.X net ended expenses $XX.X per $X.X were and of of the growth. million driven at million for and was increase as equivalents higher Our to call R&D by headcount, quarter We remarks million before period June XX, Sinai, James $X.X The for $X.XX quarter primarily at the fees was as well University $X.XX to Net Utah, fiscal $XX.X our and as Forest, Wake increased of million compared of XXXX. I'll for or 'XX for quarter cash in professional ago. same first for of studies the loss Mccullough to the XX, questions. call

James Mccullough

Thank you, James.

listing select have the with in we since recent to Nasdaq of value In become, levels, all and have markets sector revenue this substantially of tools coming intend reflect series we to stock. and addressable environments, the such November, such and markets coverage capital milestones XXXX. focus our on stock our rates, we do routes experienced specific core our from Renalytix elements business guidance specific rest testing. as opinion, of of a sector increasing in support addressable run presented the Finally, analyst continue visibility testing in not achieved pricing we year, expanding the from the provide financial up, refrain early And scale in fallen to modeling, weeks to the repeat believe oversold. at particular, stage will has as challenging diagnostics and markets, liquidity where has footprint, providing to Renalytix we while will December,

categories, Partnership, Publishing and payment call De partnerships including Advantage of market revenue FDA with appreciate And with Announcing in achieving million from Medicare across and for kidney Payment for Announcing the now For and in XXXX, one, including of Sinai please programs, operator, XXXX, achieving We growth catalysts, evidence and series pharmaceutical disease, Healthcare Novo strategic your X.X. support study six, marketing real-world a Year. safe new X. to the demonstrating and targeting multiple services segments. other New open series we authorization, insurance our than questions. and patience with System XX X. profiles, X. greater a that like Mount new diabetic have utility happy a are Medicare individuals we'd

Operator

one question ask key with you your withdraw star Instructions] comes pound your Morgan. question the on To you. Peterson [Operator a press Our from to press first may question, JP Thank telephone, Tycho

line is Your open.

Tycho Peterson

Hey, morning. good

Spoken First question, sales know just I that on Jen ramp, you hired the (ph.).

hire this XX think plan I people needs to

Tycho Peterson

Can support about bit and scaling dedicated him. that just broader all Is VA? little from you up to Salesforce? then friends the there, talk a

James Mccullough

hi. dedicated the VA. It to is Yeah, Tyco. primarily

the rules road. of of One the

rapidly. we will System, have adhering the not reimbursement Medical into sales is to we And we're and systems with are in rollout medical visibility with We There and significant VA are overhead that secured VA scale. Medical liaison now we force, national on going science hire the customer a XXX until to fixed a that that service on to start Hospital Medical going direct expand Group.

Forest, Mount additional come We at our Sinai. again salespeople, supporting scale efforts and as to the that coverage have up as that now And well. systems, insurance and continue Atrium, we hired also be get we will at other those which Wake on will into

Tycho Peterson

any FDA software. that approval What's then Are you and could any summer previously accelerate know timing, I said XXXX. out? related chance Or that? push LCD risks there And the of

James Mccullough

board. it's X-dimensional question, chess Great a Yes.

certainly do are on And very to but focused one track now, of Medicare been guidance we're LCD in market that focused it's from payment. given that expect by we pathways we've interesting other we've Washington. summer, what's an we're the playing LCD on, it the is the all follow So, back is beginning. We Ralph going dimensions. on the The the down there to post-MCIT to

will want So, do will in a I but want certainly of It terms in I FDA, think add that. that is help not Tom, open to any if also know requirement. have if you something is we that other we get XXXX. don't FDA to to up perhaps. timing pathways color

Thomas Mclain

additional helpful. know, the validation that Medicare, task clinical of majority under you laboratory Certainly. majority is tests coverage But FDA Anything of local approved with evidences are on today. cleared or them not tests, as under its The the diagnostic reimbursed tests. determinations developed

Tycho Peterson

know your also roadmap. On view? How in for out about you've I testing is repeat the talked that response monitoring. development treatment far

James Mccullough

Yes.

We haven't encouraged but evidence. timeline, put a real-world the very by development of I'm specific

think across a I we've the So, what done now of diverse value patient centers recruited implementations, geographically in core one population. for propositions multiple is we've across diverse

now we look which We metric different workflow evidence can the about is equation measure at clinical us. looking take a a are referral conversion, take performance physician talked We a at can at of physician strategies. behavior. to ways. of therapeutic look response. different in key We for real-world start at Obviously, We We can can look prescription.

testing, down a amount able XXXX start machine June of data to is Once set evidence in quarter, a and prescribe of data. we're the in that, publishing real-world development. about the patient real put particularly We're that to thing already of group, baseline certainly and to guidance quarter, the requests difference. going be we're you risk intermediate into time. want that's assessment if certainly, the and with do. a up, you risk to drug, March getting to think you with making from terms KidneyIntelX, be the then So, moving huge to And I going a high-end physicians to matter the repeat some natural going it's we've see on generate But it's of

if to if start want is patient changing to risk. affects educating patient, to the how kidney the patient, kidney If health you're behavior, that their starting you're own see and the follow you

is us development starting for And to is So, into very natural extension it's monitoring. important, therapeutic the thing roll for which now landscape mature. to a another

seeing other equation are strong which has we number Obviously, multiple are of we cancer this [Indiscernible]. in So, are pharmaceutical pipelines all over companies. therapeutics is There the inhibitors. And the Bayer again. coming have online. SGLTX

think ability identify and to the want to therapeutic have have want the the ability for be play. needs we're patients risk an a Do to stratification, You be disease acceleration therapeutics And to But risk want therapies? to now appropriate going to that's to of upfront options to ultimately a And to following. regulated tracking done to early? needs characterize in want require to and of All start pathway. assess be diagnostics to physicians. for of you what that see and all I validated lot response. there'll is understanding are you this be this you and coming precision And going patients

be So, very it's a going quickly, XXXX very now. development, of cancer how it's rich than We quicker in much comes it to data field. see in right happening it the down. area And the interesting did

Tycho Peterson

Great. year. for And one markets revenues guess still this in that When similar launching more I David, I question material? think three know small. start you're me, I for Last does are become to AstraZeneca

from do that? recognize revenues So, start you to when

James Mccullough

System. interesting equation, the we learned pharmaceutical to going very lot We've be going have XXXX. our the is to it's in from real-world I Mount Yeah, do with in a Sinai been expand. AstraZeneca think Health now collaboration. believe And in I tracking

understanding a I'd population we with surprise. we've is it's with the we're no practices, network sporadic and to the done in do of education fruitful pathway process, is deployments. true deeper The amount but survey, the disease uneven. sporadic seen different understanding this be is now the a of kidney an that where as It's and risk, kidney actually how expect around we XXXX, eye enormous physician the little that's to revenue level country. I partnerships. deployments. real-world these our should learning risk, XXXX diabetes to now number them through that different a generating in into into expect So, the the have across to to at focusing the in when up on pharmaceutical applied this. of get you veto, be of We've clinical applying comes especially discussions. are start What's along, also a the add first feed new And half It's bit developing that, is will going we're like anything moving very survey, clinical having XXXX of opener, it from the been Do And to an and partnerships physician the into real-world going we're take want strategic novel That's back clinic. look you to Tom? and And strategies. same

Thomas Mclain

see They're that target had I because has challenges been under the the value patients here area the appropriate interventions in of right this a broadly. long have opportunities roll-outs. more so really systems you approach, to seen starting underscores being health of the and driven a KidneyIntelX of think needs And for dressed the to covered we that able already now it. to course, for and that assessment risk the we're

Tycho Peterson

Thank you.

James Mccullough

Tycho you, Thank

Operator

you. Thank

with Our from Anita Berenberg comes next Dushyanth Capital. question

Your line is open.

Anita Dushyanth

morning. Thanks the please could trends cost the having until my from questions. of now. you're or seeing some KidneyIntelX's taking that Hi, up billion James, share you good for

James Mccullough

is particular focus Anita. conversion. Yes. having I other Thank on in The things you, -- what

health So, up we've This is important. population an set model. integrated

understand to We do patients. kidney in disease early diabetic and primary health risk population physicians that, engaged need to to the we have in cars assessment specialists support care

physician, Sinai, population provides their is a and visibility health Mount system And assessment. that a like so, primary said, patient risk in should have this of care

kidney then ends and in which a behavioral the which running, into test does ball component, the economics order. move that you care Now up take is, executed start converted physician primary Intelex

for in now, not a seeing, seeing at involved conversion Mount coming the couple high-risk around all actual that. is And That Now with conversion mentioned practice it's to discussion. population drug a that scripted that actually pleased orders what high. high We're in is or you and from can patients. This if independently new orders. the are done we and % especially This continues, health is where pharmacy very this rate health very very that now system. online pretended And Sinai rate by with we're but suggested you population management, Sinai that. we're prescribe trend XX Mount we're

You've completely you the changed of completely and primary change equation the equation care.

keep here, what stop So, and cut and that down you healthy of a physician primary kidney, way you act. demonstrating the better progression, a grail on the as holy get lifestyle, the start of And you you create you disease to we're care progression dialysis, cost to what now we experienced and population population without lower. launches I working. are rate in model are the getting expect is, conversion would before past, action. is that engagement that conversion integrated we we've health substantially demonstrating another this is the with health diagnostic test really This

adding we're now of Joseph's, moving Utah. adding System, University adding now We're also into St. entire the others. Wake Atrium, we're Now we CDPHP. We're demonstrated we're Forest, Health But And to scale it. adding scale. we're have VA

the primary So, we model care disease in the is are are and change level, behavior early we've population we that demonstrating in demonstrating the starting a working. health cycle at engaged physician

have published can This we thing was thousands everybody's So, that's derive because continue and this. and is evidence, you demonstrate hope. tipping adopt okay. to will real-world we from which thousands working, my now results. that a that XXXX patients to That's get point, now have I point we'll certainly to expect And peer of reviewed, when

Anita Dushyanth

versus around you follow-up end topics is, coming, And Health might the from QX. or maybe that outcome publications with check of next that, be mentioned I the Population have what helpful. the some year, a as calendar the of for I'll That's so, know you year support those to without? would one

James Mccullough

mean, benefit I Up now control quite our the now the the What's group generated applied. settings that's going right? space. in confusing. the that's of awareness format, of In has clinical which on had over we of effect. lot is care different real-world a Yeah, right of being evidence lack standard

do now short-term risk downstream see integrated have significant we expect quickly. EHR start And publication you so, the we generating will to short-term. health I And significant assessment, engaged introduce have a change a for many effect. endpoints submitted be in controlled when which could that advanced results already population you were very utility

need creating in assess changes on primary high-end game. management to physicians system-wide risk prescribe patterns Talking to referral to health patients. pharmacy the risk to the changes as intermediate drugs new changes game. a care the system disease a high-end of the Just for awareness engage risk Early population -- diabetic of for patients of kidney increase intermediate game the to basis primary care

a again, here is many years. fruit we for in this in space. have, because of many, unfortunately, we done this lot advantage we've have low-hanging oncology there the So, And

of So, slow large reminder dialysis. do Oncology want of to for reduce people can to We now number prevent clinical applying front-end who now. unsustainable. want of we kidney on applying model ultimately, And where categories, is We to And And United practiced of $XXX,XXX people emergency start start and model population course immediate upstaging Precision through groups who We end the out. This certainly order of the room. then the chemo want that and do we progression that intermediate disease. somewhere number year dialysis to that into Medicine just up the decades, a States. kidney And move crashing This it’s a we to the the is from today, % on dialysis the on applied ultimately, who space. are data completely a in it the we're That's the to then believe to as the impact. kidney have event, late-stage into naive XX disease. management. people the of with want utility reduce starts. into we've long-term going significant We the

of demographics, etc., systems market of So evidence generation eventually real-world environments, that across standard the a the patients. and in is with variety thousands change of across is healthcare kidney multiple care XX to This into chronic disease. definitive required Americans million thousands the ultimately proof

Anita Dushyanth

week, X,XXX XXX last patients And of be a Okay. be one thing Thanks is milestone. next second that It's will that. so about of rate per about about just half for by answering end the that run can low then year. screen achieved? at I what And patients number of the

James Mccullough

are want to out This we screening. not important. one point thing, just I is

prognosing are risk. disease population, to That's an next you in that point helps an already this the I Apologies. coming just on focus We're can that We year. these And adoption, diagnosed say, see now already it's to home. right? is important. population. patient and out. at in We'll very existing have go Because patients rest

paid and revenue specific testing we're be we has because We're But So, rates, inevitably patients. wrong. forecast for generation Sinai to X do now I that Mount will components. up signed run out. thousand not going rolling again, have

be comes belt Wake then Those baseline intermediate systems in patients. diabetic to risk diagnosed like numbers and up frequency into healthcare outs. population. spill. patients We VA again, diabetic see expect do We'll are -- be good target thousand to Sinai side? that We'll this that St. system available. very That in be substantiate the is think how significant obviously, Medical a is that alone intermediate the out system run-rate Again, complete data patient groups March System those that's XXX be risk high-end a We to the I target. Mount is all assessed. we the expect operating were population has as came region. registry. Is and We they Joseph's. systems, with a clinical roll high-end should figure kidney Utah, risk the Sinai week about of the see Again, what year. kidney many Forest. risk-assessed. ultimately them was believe talk of Mount able The now moving quarter June the monitored believe Health and kidney moving to Renalytix patients two XXX program should Certainly, into should have diabetes into System, of monitored. quarter. health moving achieve that XX,XXX The their in disease of Southeast that for a other a And per baseline And be the tests next disease Health University is. diabetic other and disease with Atrium like low populations. everybody the should we then when on focus them we're treatment. with again, significant

determination, creates to paid secure what to So, was securing there's Shield we're move other opening lot with addressable coverage. for expectations in private payment significant Cross determinations the Shield payer Blue lots we of a of That we for, achieve us to already I'm we Shield achieved ahead is now it of coverage actually our in that making on and broad a Blue Medicare which Blue terms achievement and that coverage is states. us first insurance We're believe an two Cross XXXX track the of Blue do receive XXXX. Blue market, announced impressed payment. are coverage gave Blue in Cross different We in our

So kidney we It's we a risk which and now have 'XX. as be disease to to more a will patients continues equation baseline creates that significant of more can footprint coverage diabetic in systems the deployed, going across assess. an build, interesting number

Anita Dushyanth

for thank you Great, that, James. helpful. Very

James Mccullough

Thank you, Anita.

Operator

you. Thank

Dan a reminder, a Stifle. we [Operator with Instruction] from Arias have As question

open. is Your line

Dan Arias

taking Yeah. Good morning. that's that clarifying XX by systems, institutions new if there. in XXXX, Number James, hospital that fiscal it can payers, What up just for a of is XXXX? And Thanks etc. number that just for that of or terms of sign farmers, for you right? Is being right? partners And you two, what questions. group my that is do couple in goal a XX tally, make-up the targeting on think you're that the points calendar period. one, then envision the you

James Mccullough

And the large course a here we pipeline. mix number regional VA intermediate The and of thank I'll get be consistency And a myself far system hospital we will with in have calendar is System. players, of So, event upside then the how you, the size. 'XX. give Dan. Medical

So, XXX Medical hospitals, as System. the VA I are said, believe, there in XXX I

systems nationally working from are the regional with VA. working also on As then on we're individual beginning, the both [Indiscernible] VA is and the we've with level the we level, which hospital said

So that calendar could very 'XX. much swing vote, which puts us in a in different position

systems I how hospital become over think are in the in do we And our clinical proposition two do and well, more years the economics. it much out discussions to the efficient And has the the the we health we only attractive. have certainly present evolved. figured more last to programs value way have this

easier. with engage hospital So, of talks in us are have discussions is to time. new systems, And we much we course, as the implementation reduce the key for

about testing to reduced in Wake in six So, was did time talk the preamble today contract implementation go Forest, we from live months. that where with

further even X X or bring months. that down expect We that to

actually we more As of streamline each management programs a management and testing a simplified care get in one with to create environment pharmacy systems. these

may Medical a believe XXXX, So, much said is end that VA we very with for doable. target we up that. success If we I is that System, XX to exceed

Let's I think the that the this model. it management team see differentiated goes, but population a certainly, how now results is with health we've very proven is It started engagement significant and pleased advantage. generating

of We on action. are risk now care them enable and with to and specific turn partnered do to large early support primary them, groups physicians assessment

the model works. know we So.,

forward lean to it. and accelerate time it's Now

Dan Arias

the institutions the as top you as on of part that under clarification more VA X one just are ones Okay, a underneath VA or multiple XX considering news of 'XX? the counting is that.

James Mccullough

an question. a open VA The That's great field us. for is

good national I even up number with think I'm hospital individual component we increase number could that looking I how contribute a that actually systems, question. think a VA rapidly. a towards or it, So a at could component, If end that's VSINs counting the if we're XX.

have now I category the emphasize So this. again, and its own is to VA

Administration a have testing pays at for all XX-year which contract result. General $XXX We per Services reportable

medical Nor original service, liaison, your regulatory is addressable I no reimbursement KidneyIntelX immediate, to do hiring force. the VA customer of market for limitation any science an systems think obviously will sales other back question, for but deployment hospital we're why opportunity XXXX. multiple have us. there. this we component We need in And present that's hiring We're

Dan Arias

Okay.

So, and revisions the be if [Indiscernible] then that towards sign you you up have. would to X that for goal and were XX in XXXX counting

James Mccullough

Tom, So, one. jumping on this

Thomas Mclain

health systems. (ph.). a XXX operate which has independently of VA are are They with The -- centers own Seabox their they network health

multiple So, systems health in each are there [Indiscernible]

Dan Arias

that before 'XX I'm trying not I'm play, within goal belabor your XXXX. for that the VA sorry, assumption you institution it guys. have but to what's

James Mccullough

the we're up I'm really it So, etc. we're Forest, let's level, I that. don't should successful then of at VSIN VA it key about Atrium, a large but in that. well to Wake when the how whole successful Sinai, Mount a upsides, at about lot have If again, level, I But have hospital different March on systems looking quarter exceed game. I But at hospital if the it independent talk systems, of we're stand the see a a talking something. make quarter. could If number, is XX plays like The national

Dan Arias

[Indiscernible]. question good a It's

James Mccullough

Thanks, Dan.

Operator

BTIG. Thank And Massaro our comes you. next Mark question from with

is line Your open.

Mark Massaro

not how end been Hey moving of handicap of for think better you the think give whether I how just anything just you FDA would comfortably, one can try secure the sense has conversation guess milestone to for us thanks process do to approval. questions. I a reviewing that going going, to when I'm and worth obviously guys, FDA understand is or and the months’ not submissions. conversations be do going the you has Can by trying 'XX? review for COVID hearing FDA creating been approval dialogue busy or value get you year just that there back to forth, fiscal is think you is

James Mccullough

been don't full as process the from believe had won't moving I color. I've So, full I've you we to -- first I give before. Thank FDA you -- I am good the application. to again, give good that's beginning, down we peak you. is game timing give FDA and call. I have will you me Mark. pinned approvals [Indiscernible] to be answer some been will have that let my timing. It's the This the said the I has a on well, hear and question

very We understanding. good a have

some We They're table. Many have - don't -oriented. these the of oriented, take is the involved. have that folks folks amount prisoners. been of significant We've very a of which third-party statistical data mentioned at expertise,

going not I I I am be in So, being been because process said, an than comment as the iterations regulatory highest I've we experienced has career. will my have That to for think The of on one inevitably more a solid that with timing are and wrong. whom and FDA agency, anybody board all similar comprehensive. we're right and many across considerable been very I'm consequence communication there's the having good, the the I been talked But track, to stress. that under FDA experiences. that of And of amount other very CEOs, for on has confident basis

we we we And what associated ask the management build come I me have very will is access obviously important. significant don't stream a don't you markets to for paid the fund and the we team come. get a other to can't ultimately focus said But force, the product, the three how you how beginning, sales because Company, know to FDA business. build number know we obviously, to intend to how the that then if of your business. worry capital we We've if In to you So, the factor the I've on build when unique. risk do will We And reimbursement things from FDA, FDA got reimbursement. a meantime, how one the how when revenue we've look, we build -- things know all product to about. said, to got you to have we with growth, this talked know know started it's FDA to

De in we're And year? that. succeeding focus. a expect marketing this my I an been FDA That fiscal much Novo I very is expectation. do. help has Do. reimbursement FDA will there. So, authorization

But component. that era. that in for nobody I How's enough? building are again, question COVID We that especially this, Did guarantee can answer the well

Mark Massaro

study primary You perfect. the can to evidence what from study journal? did. that of you us that you expect and publish we be? Sinai. you And in my then on last the then endpoints to a peer-reviewed That real-world question And Mt. was remind expect secondary Should is

James Mccullough

Yes.

healthcare very This cornerstone peer-reviewed proves larger product for that understanding out at. easy multiple evidence And it way physicians for expect go regulatory set evidence right and of very Sinai a ultimately reimbursement. a did It's the of this drives other evidence Renalytix. multiple You powerful from drives these course, versions. ultimately running and disease. real-world publications to real-world We Real-World manage it to we're up studies that the is through the should not programs. that Mount systems to pathway It beginning, case chronic is

intermediate real-world that short-term up is end-points, is with that evidence multiple long-term talked and its start in we readout it the expect we've at short looking already we've set extensive, which things conversion. machine So, about comprehensive, XXXX, like

force very for important hiring engage right? which health., By for fixed diagnostic a a deployment, a to massive engaging and capital If is sales overhead Health, you population now opposed capital marketing efficient health Population on huge [Indiscernible] proof of entire changes creating strictly with it approach. return As population And able the leading to of the we're see already physicians liquidation. large and patients reach We're investment upfront treating groups that conversion. starting to way. with push

approaching to level, my that suggested utility. orders, of or about a orders type of physician the talk have in never, XX care primary especially exceeding prepended actual we when career, executed Health Population before seen by or %. conversion So, I

Now metric. that's one

behavioral very just Now drug the they a But thing, [Indiscernible] the from behavior relatively a we That's environment not you patient the to people disease. in have nephrology. point. those physician clinical Were disease, innovation at and to should this prognostic What economics, wide new whole have this rich onto data prevent cycle, to late-stage utility, information, downstream the would it's early generate So, and this When behavior. oncology high-risk open and with in Did kidney have disease where modification? novel action, happened to they follow-up. is in is in experience kidney field, patients moving look is information maximum intervention? cancer. open around patients? we for with around this presented be case, able wide and Do open especially in referred for which

type unnoticed where partners, medical important. are gone with How service And that that are did disease. we can Ultimately, This by of a we is clinical implications that the we conversion. partners, This down different into to industry experience patients we And be entire kidney strategic evidence? has manufacturers, late-stage and implications we generate would into really around Let's starting up drugs, equation to that services, set large real-world get this not ultimately maintain short-term that slowing health? patients for But limiting networks, we've of kidney we'd maintaining dialysis. healthcare position applied. pharmaceutical integrated to ultimately, providers. show like number And show devices, are this health. have like device can progression real-world strategies of has the like management to utility we evidence across the drive now has machine

But is again, we're of reviewed ongoing can submit endpoints to able be a I I from sitting this an then to which for multiple than Salt City, in going treating to sitting own equation will the demographics peer publication evolve for people of tell going across, my significant care in number different XXXX, my you thousands different patients, in different New years. be utility speak into several here Lake facilities, patient in to is York and experience across populations. very City. So,

ratio. New with and So, physicians care Lake a and Out much to nurse come specialties. primary interaction do City, with care I in really more have primary York one-for-one down interaction I specialty your on practitioners, here than almost Salt with in City. interactions

standard prognosis. advanced details of the a in driving understand all to to if successful have you're of settings you new care these So, be going at for

for exciting is deep XXXX. I'm but equation this the off such going end creates Sorry, here, an what

Operator

[Operator you. thank Instruction] Okay, Instructions] [Operator question.

James Mccullough

a dialing New and we've and the thanks questions? of safe Again, you answered like Happy Year. please to sounds you. in, back What most everybody have Operator, for

Operator

you today's That Thank concludes call. for participating. conference

may [Operator disconnect. Instruction] now You

Renalytix (RTNXF) 8 Dec 212022 Q1 Earnings call transcript